MX9700890A - 1, 4-benzotiazepina-1, 1-dioxidos hipolipidemicos. - Google Patents
1, 4-benzotiazepina-1, 1-dioxidos hipolipidemicos.Info
- Publication number
- MX9700890A MX9700890A MX9700890A MX9700890A MX9700890A MX 9700890 A MX9700890 A MX 9700890A MX 9700890 A MX9700890 A MX 9700890A MX 9700890 A MX9700890 A MX 9700890A MX 9700890 A MX9700890 A MX 9700890A
- Authority
- MX
- Mexico
- Prior art keywords
- hypolipidemic
- benzothiazepine
- dioxides
- novel
- prophylaxis
- Prior art date
Links
- 230000000055 hyoplipidemic effect Effects 0.000 title abstract 2
- IVGHNDNOFMTFMK-UHFFFAOYSA-N 1$l^{6},4-benzothiazepine 1,1-dioxide Chemical class O=S1(=O)C=CN=CC2=CC=CC=C12 IVGHNDNOFMTFMK-UHFFFAOYSA-N 0.000 title 1
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D281/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D281/02—Seven-membered rings
- C07D281/04—Seven-membered rings having the hetero atoms in positions 1 and 4
- C07D281/08—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D281/10—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6536—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and sulfur atoms with or without oxygen atoms, as the only ring hetero atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Biochemistry (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Steroid Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
La invencion se refiere a los compuestos hipolipidémicos nuevos de la formula (I), con los procesos y los intermediarios nuevos para su preparacion, las composiciones farmacéuticas que los contienen y con su uso en la medicina, en forma particular en la profilaxis y en el tratamiento de las condiciones hiperlipidémicas, tales como la aterosclerosis.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US28852794A | 1994-08-10 | 1994-08-10 | |
PCT/GB1995/001884 WO1996005188A1 (en) | 1994-08-10 | 1995-08-09 | Hypolipidemic 1,4-benzothiazepine-1,1-dioxides |
Publications (1)
Publication Number | Publication Date |
---|---|
MX9700890A true MX9700890A (es) | 1997-04-30 |
Family
ID=23107516
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX9700890A MX9700890A (es) | 1994-08-10 | 1995-08-09 | 1, 4-benzotiazepina-1, 1-dioxidos hipolipidemicos. |
Country Status (31)
Country | Link |
---|---|
US (1) | US5910494A (es) |
EP (2) | EP0775126B1 (es) |
JP (1) | JP2935756B2 (es) |
KR (1) | KR100354288B1 (es) |
CN (1) | CN1059673C (es) |
AP (1) | AP720A (es) |
AT (1) | ATE226946T1 (es) |
AU (1) | AU696073B2 (es) |
BG (1) | BG62048B1 (es) |
BR (1) | BR9508586A (es) |
CA (1) | CA2197099A1 (es) |
CZ (1) | CZ37397A3 (es) |
DE (1) | DE69528704T2 (es) |
DK (1) | DK0775126T3 (es) |
EE (1) | EE9700028A (es) |
ES (1) | ES2185711T3 (es) |
FI (1) | FI970531A0 (es) |
HK (1) | HK1003936A1 (es) |
HU (1) | HUT77129A (es) |
IL (1) | IL114877A (es) |
IS (1) | IS4418A (es) |
MX (1) | MX9700890A (es) |
NO (1) | NO308131B1 (es) |
NZ (1) | NZ290911A (es) |
OA (1) | OA10597A (es) |
PL (1) | PL184512B1 (es) |
PT (1) | PT775126E (es) |
RU (1) | RU2156245C2 (es) |
SK (1) | SK17797A3 (es) |
WO (1) | WO1996005188A1 (es) |
ZA (1) | ZA956647B (es) |
Families Citing this family (99)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6642268B2 (en) | 1994-09-13 | 2003-11-04 | G.D. Searle & Co. | Combination therapy employing ileal bile acid transport inhibiting benzothipines and HMG Co-A reductase inhibitors |
US5994391A (en) * | 1994-09-13 | 1999-11-30 | G.D. Searle And Company | Benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake |
US6268392B1 (en) | 1994-09-13 | 2001-07-31 | G. D. Searle & Co. | Combination therapy employing ileal bile acid transport inhibiting benzothiepines and HMG Co-A reductase inhibitors |
US6262277B1 (en) | 1994-09-13 | 2001-07-17 | G.D. Searle And Company | Intermediates and processes for the preparation of benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake |
US6107494A (en) * | 1994-09-13 | 2000-08-22 | G.D. Searle And Company | Substituted 5-aryl-benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake |
GB9423172D0 (en) * | 1994-11-17 | 1995-01-04 | Wellcom Foundation The Limited | Hypolipidemic benzothiazepines |
GB9704208D0 (en) * | 1997-02-28 | 1997-04-16 | Glaxo Group Ltd | Chemical compounds |
PT864582E (pt) * | 1997-03-14 | 2003-10-31 | Aventis Pharma Gmbh | 1,4-benzotiazepina-1,1-dioxidos hipolipidemicos |
GB9800428D0 (en) | 1998-01-10 | 1998-03-04 | Glaxo Group Ltd | Chemical compounds |
PT1140184E (pt) | 1998-12-23 | 2003-10-31 | Searle Llc | Combinacoes de inibidores de proteina de transferencia de ester de colesterilo com derivados de acido nicotinico para indicacoes cardiovasculares |
AU2157400A (en) | 1998-12-23 | 2000-07-31 | G.D. Searle & Co. | Combinations of cholesteryl ester transfer protein inhibitors and hmg coa reductase inhibitors for cardiovascular indications |
WO2000038723A1 (en) | 1998-12-23 | 2000-07-06 | G.D. Searle Llc | Combinations of cholesteryl ester transfer protein inhibitors and bile acid sequestering agents for cardiovascular indications |
CN1338944A (zh) | 1998-12-23 | 2002-03-06 | G.D.瑟尔有限公司 | 用于心血管适应症的胆固醇酯转移蛋白抑制剂和苯氧异丁酸类衍生物的联合形式 |
ES2189529T3 (es) | 1998-12-23 | 2003-07-01 | Searle Llc | Combinaciones de inhiidores para el transporte de acidos biliares en el ileon y agentes complejantes para indicaciones cardiovasculares. |
PL348580A1 (en) | 1998-12-23 | 2002-06-03 | Searle Llc | Combinations of ileal bile acid transport inhibitors and fibric acid derivatives for cardiovascular indications |
EP1342475A1 (en) | 1998-12-23 | 2003-09-10 | G.D. Searle LLC. | Combinations of ileal bile acid transport inhibitors and cholesteryl ester transfer protein inhibitors for cardiovascular indications |
AU3694600A (en) * | 1999-02-12 | 2000-08-29 | G.D. Searle Llc | Novel 1,2-benzothiazepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake |
DE19916108C1 (de) | 1999-04-09 | 2001-01-11 | Aventis Pharma Gmbh | Mit Zuckerresten substituierte 1,4-Benzothiazepin-1,1-dioxidderivate, Verfahren zu deren Herstellung und deren Verwendung |
GB9914745D0 (en) * | 1999-06-24 | 1999-08-25 | Knoll Ag | Therapeutic agents |
FR2796070B1 (fr) | 1999-07-06 | 2003-02-21 | Lipha | Derives de benzodiazepines utilisables dans le traitement de dyslipidemies, de l'atherosclerose et du diabete, compositions pharmaceutiques les contenant et procedes de preparation |
SE0000772D0 (sv) | 2000-03-08 | 2000-03-08 | Astrazeneca Ab | Chemical compounds |
US6794544B2 (en) | 2000-03-10 | 2004-09-21 | Pharmacia Corporation | Method for the preparation of tetrahydrobenzothiepines |
US7393652B2 (en) | 2000-05-10 | 2008-07-01 | The Trustees Of Columbia University In The City Of New York | Methods for identifying a chemical compound that directly enhances binding of FKBP12.6 to PKA-phosphorylated type 2 ryanodine receptor (RyR2) |
US7718644B2 (en) | 2004-01-22 | 2010-05-18 | The Trustees Of Columbia University In The City Of New York | Anti-arrhythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) and uses thereof |
US7879840B2 (en) | 2005-08-25 | 2011-02-01 | The Trustees Of Columbia University In The City Of New York | Agents for preventing and treating disorders involving modulation of the RyR receptors |
US8022058B2 (en) | 2000-05-10 | 2011-09-20 | The Trustees Of Columbia University In The City Of New York | Agents for preventing and treating disorders involving modulation of the RyR receptors |
US20020183307A1 (en) * | 2000-07-26 | 2002-12-05 | Tremont Samuel J. | Novel 1,4-benzothiazephine and 1,5-benzothiazepine compounds as inhibitors of apical sodium co-dependent bile acid transport and taurocholate uptake |
WO2003079972A2 (en) | 2002-02-22 | 2003-10-02 | New River Parmaceuticals Inc. | Active agent delivery systems and methods for protecting and administering active agents |
EG26979A (en) | 2000-12-21 | 2015-03-01 | Astrazeneca Ab | Chemical compounds |
WO2002053548A1 (en) * | 2000-12-27 | 2002-07-11 | Banyu Pharmaceutical Co.,Ltd. | Benzothiazepine derivatives |
GB0121337D0 (en) * | 2001-09-04 | 2001-10-24 | Astrazeneca Ab | Chemical compounds |
GB0121621D0 (en) * | 2001-09-07 | 2001-10-31 | Astrazeneca Ab | Chemical compounds |
GB0121622D0 (en) | 2001-09-07 | 2001-10-31 | Astrazeneca Ab | Chemical compounds |
EP1427423B9 (en) | 2001-09-08 | 2017-12-20 | AstraZeneca AB | Benzothiazepine and benzothiadiazepine derivatives with ileal bile acid transport (ibat) inhibitory activity for the treatment hyperlipidaemia |
JP2005518347A (ja) | 2001-11-02 | 2005-06-23 | ジー.ディー. サール エルエルシー | 頂端ナトリウム共依存性胆汁酸輸送(asbt)およびタウロコール酸塩取り込みの阻害剤としての新規一および二フッ化ベンゾチエピン化合物 |
MXPA04006255A (es) | 2002-01-17 | 2004-09-27 | Pharmacia Corp | Compuestos novedosos de alquil/aril hidroxi o ceto tiepina como inhibidores del transporte del acido biliar codependiente del sodio apical y la captacion de taurocolato. |
GB0209467D0 (en) | 2002-04-25 | 2002-06-05 | Astrazeneca Ab | Chemical compounds |
GB0213669D0 (en) | 2002-06-14 | 2002-07-24 | Astrazeneca Ab | Chemical compounds |
US7312208B2 (en) | 2002-08-28 | 2007-12-25 | Asahi Kasei Pharma Corporation | Quaternary ammonium compounds |
US7544678B2 (en) | 2002-11-05 | 2009-06-09 | The Trustees Of Columbia University In The City Of New York | Anti-arrythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) |
GB0304194D0 (en) * | 2003-02-25 | 2003-03-26 | Astrazeneca Ab | Chemical compounds |
AU2004220548A1 (en) | 2003-03-07 | 2004-09-23 | The Trustees Of Columbia University, In The City Of New York | Type 1 ryanodine receptor-based methods |
GB0307918D0 (en) | 2003-04-05 | 2003-05-14 | Astrazeneca Ab | Therapeutic use |
US8710045B2 (en) | 2004-01-22 | 2014-04-29 | The Trustees Of Columbia University In The City Of New York | Agents for preventing and treating disorders involving modulation of the ryanodine receptors |
CN1930137B (zh) * | 2004-02-27 | 2011-07-20 | 旭化成制药株式会社 | 苯并硫氮杂卓和苯并虑平化合物 |
US7704990B2 (en) | 2005-08-25 | 2010-04-27 | The Trustees Of Columbia University In The City Of New York | Agents for preventing and treating disorders involving modulation of the RyR receptors |
CA2744817C (en) | 2008-11-26 | 2020-07-07 | Satiogen Pharmaceuticals, Inc. | Bile acid recycling inhibitors for treatment of obesity and diabetes |
JO3131B1 (ar) * | 2010-04-27 | 2017-09-20 | Glaxosmithkline Llc | مركبات كيميائية |
EP2575821B1 (en) | 2010-05-26 | 2015-08-12 | Satiogen Pharmaceuticals, Inc. | Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions |
CA2815698C (en) | 2010-11-08 | 2019-04-30 | Albireo Ab | A pharmaceutical combination comprising an ibat inhibitor and a bile acid binder |
RS57778B1 (sr) | 2010-11-08 | 2018-12-31 | Albireo Ab | Inhibitori crevnog transportera žučne kiseline (ibat) za lečenje bolesti jetre |
JP2015003861A (ja) * | 2011-10-18 | 2015-01-08 | 株式会社カネカ | (r)−2−アミノ−2−エチルヘキサノールの製造法 |
KR20190135545A (ko) | 2011-10-28 | 2019-12-06 | 루메나 파마수티컬즈, 인코포레이티드 | 고담혈증 및 담즙 정체성 간 질환 치료용 담즙산 재순환 억제제 |
MX369466B (es) | 2011-10-28 | 2019-11-08 | Lumena Pharmaceuticals Inc | Inhibidores de la recirculación de ácidos biliares para el tratamiento de enfermedades hepáticas colestásicas pediátricas. |
JP2016514684A (ja) | 2013-03-15 | 2016-05-23 | ルメナ ファーマシューティカルズ エルエルシー | 原発性硬化性胆管炎および炎症性腸疾患の処置のための胆汁酸再循環阻害剤 |
MX2015013196A (es) | 2013-03-15 | 2016-04-15 | Lumena Pharmaceuticals Inc | Inhibidores de reciclaje de acidos biliares para el tratamiento de la enfermedad de reflujo gastroesofagico y esofago de barrett. |
JO3301B1 (ar) | 2013-04-26 | 2018-09-16 | Albireo Ab | تعديلات بلورية على إيلوبيكسيبات |
KR102560954B1 (ko) | 2014-06-25 | 2023-07-31 | 이에이 파마 가부시키가이샤 | 고형 제제 및 그의 착색 방지 또는 착색 감소 방법 |
KR20170039195A (ko) | 2014-08-05 | 2017-04-10 | 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 | 벤조티아제핀의 합성 |
EP3012252A1 (en) | 2014-10-24 | 2016-04-27 | Ferring BV | Crystal modifications of elobixibat |
ES2874669T3 (es) | 2016-02-09 | 2021-11-05 | Albireo Ab | Formulación oral de colestiramina y uso de la misma |
US10786529B2 (en) | 2016-02-09 | 2020-09-29 | Albireo Ab | Oral cholestyramine formulation and use thereof |
US10441604B2 (en) | 2016-02-09 | 2019-10-15 | Albireo Ab | Cholestyramine pellets and methods for preparation thereof |
US10441605B2 (en) | 2016-02-09 | 2019-10-15 | Albireo Ab | Oral cholestyramine formulation and use thereof |
CN108601745B (zh) | 2016-02-09 | 2021-12-07 | 阿尔比里奥公司 | 口服考来烯胺制剂及其用途 |
EP3664782A1 (en) | 2017-08-09 | 2020-06-17 | Albireo AB | Cholestyramine pellets, oral cholestyramine formulations and use thereof |
JP2020530448A (ja) | 2017-08-09 | 2020-10-22 | アルビレオ・アクチボラグ | コレスチラミン顆粒、経口コレスチラミン製剤、及びそれらの使用 |
TW202015699A (zh) | 2018-06-05 | 2020-05-01 | 瑞典商艾爾比瑞歐公司 | 苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽汁酸調節劑之用途 |
US10793534B2 (en) | 2018-06-05 | 2020-10-06 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
WO2019245449A1 (en) | 2018-06-20 | 2019-12-26 | Albireo Ab | Pharmaceutical formulation of odevixibat |
US11801226B2 (en) | 2018-06-20 | 2023-10-31 | Albireo Ab | Pharmaceutical formulation of odevixibat |
US11007142B2 (en) | 2018-08-09 | 2021-05-18 | Albireo Ab | Oral cholestyramine formulation and use thereof |
US10722457B2 (en) | 2018-08-09 | 2020-07-28 | Albireo Ab | Oral cholestyramine formulation and use thereof |
US11549878B2 (en) | 2018-08-09 | 2023-01-10 | Albireo Ab | In vitro method for determining the adsorbing capacity of an insoluble adsorbant |
US10941127B2 (en) | 2019-02-06 | 2021-03-09 | Albireo Ab | Benzothiadiazepine compounds and their use as bile acid modulators |
US10975045B2 (en) | 2019-02-06 | 2021-04-13 | Aibireo AB | Benzothiazepine compounds and their use as bile acid modulators |
FI3921028T3 (fi) | 2019-02-06 | 2023-01-31 | Bentsotiadiatsepiinin yhdisteet ja niiden käyttö sappihapon modulaattoreina | |
EP3921027B1 (en) | 2019-02-06 | 2023-07-19 | Albireo AB | Benzothiazepine compounds and their use as bile acid modulators |
KR20210137046A (ko) | 2019-02-12 | 2021-11-17 | 미룸 파마슈티컬스, 인크. | 담즙정체의 치료 방법 |
TW202134223A (zh) | 2019-12-04 | 2021-09-16 | 瑞典商艾爾比瑞歐公司 | 苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽酸調節劑之用途 |
EP4069359B1 (en) | 2019-12-04 | 2024-01-03 | Albireo AB | Benzothia(di)azepine compounds and their use as bile acid modulators |
AR120683A1 (es) | 2019-12-04 | 2022-03-09 | Albireo Ab | Compuestos de benzoti(di)azepina y su uso como ácido biliar |
US11014898B1 (en) | 2020-12-04 | 2021-05-25 | Albireo Ab | Benzothiazepine compounds and their use as bile acid modulators |
AR120682A1 (es) | 2019-12-04 | 2022-03-09 | Albireo Ab | Compuestos de benzotiadiazepina y su uso como moduladores del ácido biliar |
WO2021110887A1 (en) | 2019-12-04 | 2021-06-10 | Albireo Ab | Benzothiazepine compounds and their use as bile acid modulators |
CR20220315A (es) | 2019-12-04 | 2022-10-26 | Albireo Ab | Compuestos de benzoti(di)azepina y su uso como moduladores del ácido biliar |
TW202134220A (zh) | 2019-12-04 | 2021-09-16 | 瑞典商艾爾比瑞歐公司 | 苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽酸調節劑之用途 |
ES2973355T3 (es) | 2019-12-04 | 2024-06-19 | Albireo Ab | Compuestos de benzotia(di)azepina y su uso como moduladores del ácido biliar |
EP4069247A1 (en) | 2019-12-04 | 2022-10-12 | Albireo AB | Benzothiadiazepine compounds and their use as bile acid modulators |
EP4188541A1 (en) | 2020-08-03 | 2023-06-07 | Albireo AB | Benzothia(di)azepine compounds and their use as bile acid modulators |
WO2022029101A1 (en) | 2020-08-03 | 2022-02-10 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
KR20230106651A (ko) | 2020-11-12 | 2023-07-13 | 알비레오 에이비 | 진행성 가족성 간내 담즙정체증(pfic)을 치료하기 위한 오데빅시바트 |
WO2022101379A1 (en) | 2020-11-12 | 2022-05-19 | Albireo Ab | Odevixibat for treating progressive familial intrahepatic cholestasis (pfic) |
AU2021390172A1 (en) | 2020-12-04 | 2023-06-22 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
TW202313579A (zh) | 2021-06-03 | 2023-04-01 | 瑞典商艾爾比瑞歐公司 | 苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽酸調節劑之用途 |
US20230398125A1 (en) | 2022-06-09 | 2023-12-14 | Albireo Ab | Treating hepatitis |
US20240067617A1 (en) | 2022-07-05 | 2024-02-29 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
US20240173333A1 (en) | 2022-11-03 | 2024-05-30 | Albireo Ab | Treating Alagille Syndrome (ALGS) |
US20240207286A1 (en) | 2022-12-09 | 2024-06-27 | Albireo Ab | Asbt inhibitors in the treatment of renal diseases |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3362962A (en) * | 1964-01-24 | 1968-01-09 | Hoffmann La Roche | Certain benzothiazepine derivatives |
US4564612A (en) * | 1983-04-22 | 1986-01-14 | Takeda Chemical Industries, Ltd. | Condensed, seven-membered ring compounds and their use |
GB9111376D0 (en) * | 1991-05-25 | 1991-07-17 | Boots Co Plc | Therapeutic agents |
GB9203347D0 (en) * | 1992-02-17 | 1992-04-01 | Wellcome Found | Hypolipidaemic compounds |
US5276025A (en) * | 1992-09-09 | 1994-01-04 | Merck & Co., Inc. | Heterobicyclic sulfonamides |
IL108634A0 (en) * | 1993-02-15 | 1994-05-30 | Wellcome Found | Hypolipidaemic heterocyclic compounds, their prepatation and pharmaceutical compositions containing them |
ZA941003B (en) * | 1993-02-15 | 1995-08-14 | Wellcome Found | Hypolipidaemic compounds |
PT781278E (pt) * | 1994-09-13 | 2001-08-30 | Monsanto Co | Novas benzotiepinas com actividade inibidora do transporte de acido biliar ileal e da remocao do taurocolato |
GB9423172D0 (en) * | 1994-11-17 | 1995-01-04 | Wellcom Foundation The Limited | Hypolipidemic benzothiazepines |
-
1995
- 1995-08-08 ZA ZA9506647A patent/ZA956647B/xx unknown
- 1995-08-09 KR KR1019970700845A patent/KR100354288B1/ko not_active IP Right Cessation
- 1995-08-09 SK SK177-97A patent/SK17797A3/sk unknown
- 1995-08-09 RU RU97104002/04A patent/RU2156245C2/ru active
- 1995-08-09 PL PL95318496A patent/PL184512B1/pl unknown
- 1995-08-09 AU AU44260/96A patent/AU696073B2/en not_active Ceased
- 1995-08-09 EE EE9700028A patent/EE9700028A/xx unknown
- 1995-08-09 EP EP95927877A patent/EP0775126B1/en not_active Expired - Lifetime
- 1995-08-09 US US08/793,040 patent/US5910494A/en not_active Expired - Fee Related
- 1995-08-09 AT AT95927877T patent/ATE226946T1/de not_active IP Right Cessation
- 1995-08-09 BR BR9508586A patent/BR9508586A/pt not_active Application Discontinuation
- 1995-08-09 IL IL11487795A patent/IL114877A/xx active IP Right Grant
- 1995-08-09 AP APAP/P/1997/000920A patent/AP720A/en active
- 1995-08-09 JP JP8507116A patent/JP2935756B2/ja not_active Expired - Lifetime
- 1995-08-09 DK DK95927877T patent/DK0775126T3/da active
- 1995-08-09 NZ NZ290911A patent/NZ290911A/en unknown
- 1995-08-09 DE DE69528704T patent/DE69528704T2/de not_active Expired - Fee Related
- 1995-08-09 CZ CZ97373A patent/CZ37397A3/cs unknown
- 1995-08-09 EP EP02003711A patent/EP1203769A1/en not_active Withdrawn
- 1995-08-09 ES ES95927877T patent/ES2185711T3/es not_active Expired - Lifetime
- 1995-08-09 HU HU9700408A patent/HUT77129A/hu active IP Right Revival
- 1995-08-09 CA CA002197099A patent/CA2197099A1/en not_active Abandoned
- 1995-08-09 WO PCT/GB1995/001884 patent/WO1996005188A1/en active IP Right Grant
- 1995-08-09 PT PT95927877T patent/PT775126E/pt unknown
- 1995-08-09 CN CN95195419A patent/CN1059673C/zh not_active Expired - Fee Related
- 1995-08-09 MX MX9700890A patent/MX9700890A/es unknown
-
1997
- 1997-01-24 IS IS4418A patent/IS4418A/is unknown
- 1997-02-06 OA OA60961A patent/OA10597A/en unknown
- 1997-02-07 BG BG101209A patent/BG62048B1/bg unknown
- 1997-02-07 NO NO970585A patent/NO308131B1/no not_active IP Right Cessation
- 1997-02-07 FI FI970531A patent/FI970531A0/fi unknown
-
1998
- 1998-04-15 HK HK98103105A patent/HK1003936A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX9700890A (es) | 1, 4-benzotiazepina-1, 1-dioxidos hipolipidemicos. | |
MX9703546A (es) | Benzotiazepinas hipolipidemicas. | |
WO2000047568A3 (en) | 1,2-benzothiazepines for the treatment of hyperlipidemic diseases | |
AP2000001860A0 (en) | Hypolipidemic benzothiazepine compounds. | |
CA2231971A1 (en) | Hypolipidemic 1,4-benzothiazepine-1,1-dioxides | |
IL110031A0 (en) | Phenyl heterocycles, their manufacture and pharmaceutical compositions containing them | |
IL112074A0 (en) | Branched-amino-substituted thiazoles, their preparation and pharmaceutical compositions containing them | |
MY112944A (en) | Enterokinetic benzamide | |
ZA984114B (en) | Substituted heterocyclic compounds a process for the preparation thereof and pharmaceutical compositions containing them | |
ATE110568T1 (de) | Pharmazeutisches präparat zur behandlung des katarakts. | |
ZA903111B (en) | 2-hydroxy-3-phenoxypropylamino compounds and pharmaceutical compositions containing them | |
ZA872276B (en) | Pharmaceutical compositions containing 5-phenyl-1,3-dioxoalkenyl compounds | |
ZA929846B (en) | Nitrile and aldoxime indane compounds and compositions | |
IL87197A0 (en) | Leukotriene antagonists,precursors of same,processes for the preparation thereof and pharmaceutical compositions containing same | |
GEP20002095B (en) | Antracycline Disaccharides, Process for Their Preparation and Pharmaceutical Compositions | |
GR3015706T3 (en) | Benzylselenobenzamides of aminopyridines and picolylamines. | |
JO1711B1 (en) | Therapeutic agents |